Singapore markets closed
  • Straits Times Index

    2,537.39
    +8.98 (+0.36%)
     
  • Nikkei

    23,516.59
    +42.32 (+0.18%)
     
  • Hang Seng

    24,918.78
    +132.65 (+0.54%)
     
  • FTSE 100

    5,860.28
    +74.63 (+1.29%)
     
  • BTC-USD

    12,961.37
    +64.78 (+0.50%)
     
  • CMC Crypto 200

    260.05
    -1.40 (-0.54%)
     
  • S&P 500

    3,465.39
    +11.90 (+0.34%)
     
  • Dow

    28,335.57
    -28.09 (-0.10%)
     
  • Nasdaq

    11,548.28
    +42.28 (+0.37%)
     
  • Gold

    1,903.40
    -1.20 (-0.06%)
     
  • Crude Oil

    39.78
    -0.86 (-2.12%)
     
  • 10-Yr Bond

    0.8410
    -0.0070 (-0.83%)
     
  • FTSE Bursa Malaysia

    1,494.64
    -4.16 (-0.28%)
     
  • Jakarta Composite Index

    5,112.19
    +20.37 (+0.40%)
     
  • PSE Index

    6,484.06
    +139.43 (+2.20%)
     

Endo starts manufacturing Novavax's potential COVID-19 vaccine

·1-min read
FILE PHOTO: A small bottle labeled with a "Vaccine" sticker is held near a medical syringe in front of displayed "Coronavirus COVID-19" words in this illustration
FILE PHOTO: A small bottle labeled with a "Vaccine" sticker is held near a medical syringe in front of displayed "Coronavirus COVID-19" words in this illustration

(Reuters) - Generic drugmaker Endo said on Friday it was manufacturing Novavax Inc's <NVAX.O> experimental COVID-19 vaccine, sending its shares up 10% before the trading bell.

The news comes a day after Novavax launched a late-stage trial of the vaccine candidate, NVX‑CoV2373, in the United Kingdom.

Endo said it has signed a deal with Novavax and its unit Par Sterile has begun production of the final drug product, with initial batches to be used in Novavax's phase-3 clinical trial in the United States.

Financials and other terms of the non-exclusive agreement were not disclosed.

NVX‑CoV2373 is currently also being tested in two ongoing mid-stage trials that began in August.

(Reporting by Manas Mishra and Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)